Phase I-II

Business booms for PPD

Business booms for PPD

By Kirsty Barnes

As global contract research spending remains robust, business is
booming for Pharmaceutical Product Development (PPD) as the US firm
reported a surge in sales, profits and new business for its second
quarter 2006.

New CRO on the Phase I scene

New CRO on the Phase I scene

By Kirsty Barnes

A new Phase I clinical services company, Roanoke Clinical Research
(RCR), has been formed to relieve pressure in the biopharma
industry as it continues to face bottlenecks in early stage
research and struggles to move forward fast...

French CROs join forces

French CROs join forces

By Kirsty Barnes

Two French clinical research organisations (CROs), PharmaScan and
ClinicalLand, have joined forces to accelerate their growth and
reinforce their presence in the competitive clinical trials sector.

Balancing the clinical scales

Outsourcing-Pharma focus on: cutting the cost of clinical trials

Balancing the clinical scales

By Kirsty Barnes

As pharma companies flock towards Eastern Europe and India in a bid
to cut direct clinical trial costs, does outsourcing actually
translate into real world cost-savings?

Use 'The Net' to catch your fish

Outsourcing-Pharma Focus: Cutting the cost of clinical trials

Use 'The Net' to catch your fish

By Kirsty Barnes

Patient recruitment consumes more time than any other clinical
trial activity, costing the industry millions of dollars. However,
recruiting patients on the Internet can slash recruitment times and
bring drugs to market faster.

PRA moves profits forward

PRA moves profits forward

By Kirsty Barnes

Despite a dip in revenue, PRA International saw its profit grow 53
per cent in the fourth quarter of 2005 to reach $7.5m (€6.3m) on
the back of improved margins. The global clinical research
organization (CRO) also saw a similar growth...

Covance ends 2005 on the upswing

Covance ends 2005 on the upswing

By Kirsty Barnes

Covance closed 2005 on a high after net revenues climbed 16.9 per
cent from 2004 to reach $1.19 bn (€1 bn). The current trend towards
outsourcing R&D, coupled with increased productivity and repeat
business has fuelled the company's...

Follow us

Product Innovations